iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

iCAD, Inc.

RMS Medical Devices is specialized in the development, support, and distribution of supplies, instruments, and services for health practitioners. The company offers solutions for minimally invasive diagnostics and therapies in various medical fields.

RMS Medical Devices

iCAD develops artificial intelligence solutions for cancer detection, specifically focusing on breast cancer screening and assessment. The company provides AI-powered tools for detection, density assessment, and risk evaluation.

Metric
Company Name	iCAD, Inc.	RMS Medical Devices
Symbol	ICAD
MSH ID	COM:ICADMED	COM:RMSMEDICALDEVICES
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Medical - Devices	Medical Devices
Country	US	BE
Stage	Post-IPO Equity
Employee Count	67
Website	icadmed.com	rmsmedicaldevices.com
LinkedIn		rms-medicaldevices
Founders

Metric
Market Cap	34.50M
Enterprise Value
Monthly Web Traffic	5.93K
Web Traffic Growth	0.32
Valuation
Raised Capital	22M

Metric
Revenue	17.32M
Revenue (LTM)
Revenue (NTM)
Gross Profit	14.54M
EBITDA	-7.28M
Operating Income	-7.69M
Net Income	-4.85M
EPS	-0.19
Diluted EPS	-0.19
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.85
Operating Profit Margin	-0.27
EBITDA Margin	-0.42
Net Profit Margin	-0.15
Return on Equity	-0.09
Return on Assets	-0.07
Return on Capital Employed	-0.15

COM:ICADMED

iCAD

Last Close

1.54

22/11 21:00

Market Cap

34.50M

Beta: -

Volume Today

171.23K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-3.49
P/B Ratio	1.12
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.75
EV Multiple	-8.47

Metric
Days Sales Outstanding	79.97
Days Payables Outstanding	71.96
Days Inventory Outstanding	91.54
Operating Cycle	201.87
Cash Conversion Cycle	134.68
Asset Turnover	0.49

Metric
Operating Cash Flow	-4.48M
Free Cash Flow	-5.76M
Cash Flow to Debt
Operating Cash Flow/Sales	-0.21
Free Cash Flow Yield	-0.21

Metric
Cash & Equivalents	21.67M
Accounts Receivable	-1.75M
Inventory	917K
Goodwill	8.36M
Debt to Capitalization	0.02
Debt to Assets	0.01
Current Ratio	2.83
Quick Ratio	4.59

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.06
R&D to Revenue	0.29
SG&A to Revenue	0.48